The results of a newly published network meta-analysis by Kongmalai et al. [61], involving 2252 patients from 31 randomized controlled trials, demonstrated that the addition of GLP-1 agonists to the standard of care in NAFLD patients’ treatment led to a significant reduction in intrahepatic steatosis (IHS) when compared to the standard treatment alone. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.